ICUI ICU MEDICAL INC/DE
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 883984 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-5.9%
TTM net income YoY919.5%
TTM EPS YoY846.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—
Margins
Gross margin40.3%
Operating margin5.1%
Net margin2.8%
FCF margin9.6%
EBITDA margin11.2%
Returns
ROE2.8%
ROA1.5%
ROIC (approx.)3.6%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets44.4%
Debt / equity0.53x
Current ratio2.37x
Interest coverage1.41x
Cash quality & payout
Operating cash flow / net income4.63x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.23B | $2.38B |
| Cost of revenue | $1.41B | $1.56B |
| Gross profit | $822.04M | $824.78M |
| R&D expense | $87.50M | $88.61M |
| SG&A expense | $625.21M | $638.76M |
| Operating income | $42.83M | $42.96M |
| Interest expense | $93.34M | $106.54M |
| Pretax income | $4.36M | -$66.01M |
| Income tax | $2.44M | $51.68M |
| Net income | $732,000 | -$117.69M |
| EBITDA | $243.57M | $262.48M |
| EPS (basic) | 0.03 | -4.83 |
| EPS (diluted) | 0.03 | -4.83 |
| Weighted avg. shares (diluted) | 24.90M | 24.39M |
| Banking | ||
| Net interest income | -$83.03M | -$95.75M |
| Balance sheet | ||
| Cash & equivalents | $307.96M | $308.57M |
| Short-term investments | — | $0 |
| Receivables | $180.51M | $182.83M |
| Inventory | $615.86M | $584.68M |
| Current assets | $1.19B | $1.44B |
| PP&E, net | $451.82M | $442.75M |
| Goodwill | $1.50B | $1.43B |
| Intangibles | $633.56M | $740.79M |
| Total assets | $4.05B | $4.20B |
| Current liabilities | $498.86M | $556.18M |
| Short-term debt | $18.75M | $51.00M |
| Long-term debt | $1.27B | $1.53B |
| Total debt | $1.28B | $1.58B |
| Total liabilities | $1.93B | $2.24B |
| Shareholders' equity | $2.12B | $1.97B |
| Net debt | $976.70M | $1.27B |
| Shares outstanding | 24.69M | 24.52M |
| Cash flow statement | ||
| Operating cash flow | $179.85M | $204.03M |
| Capital expenditure | $88.04M | $79.37M |
| Free cash flow | $91.80M | $124.66M |
| Investing cash flow | $122.23M | -$88.96M |
| Financing cash flow | -$311.52M | -$55.80M |
| Depreciation & amortization | $200.74M | $219.51M |
| Stock-based compensation | $55.76M | $46.88M |
| Share buybacks | $8.77M | $11.99M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.